Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues

World Journal of Gastroenterology

Volumn 16, Issue 10, 2010, Pages 1274-1278

  Li, Qian ^a   Peng, Jie ^a   Li, Xin Hua ^a   Liu, Ting ^a   Liang, Qing Chun ^a   Zhang, Gui Ying ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Fas; Fas ligand fasL; Gastric carcinoma; Lymph nodes

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA;

EID: 77950178296     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i10.1274     Document Type: Article

References (19)

1. Kase S, Osaki M, Adachi H, Kaibara N, Ito H. Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas. Int J Oncol 2002; 20: 291-297
2. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack. Dis Esophagus 1999; 12: 83-89
3. Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R, Nagasue N. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res 1999; 5: 2464-2469
4. Zhu Q, Liu JY, Xu HW, Yang CM, Zhang AZ, Cui Y, Wang HB. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system. World J Gastroenterol 2005; 11: 6125-6129
5. Xu LN, Zou SQ, Wang JM. Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma. World J Gastroenterol 2005; 11: 3719-3723
6. Younes M, Schwartz MR, Finnie D, Younes A. Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus. Hum Pathol 1999; 30: 1309-1313
7. Li YZ, Zhao P, Han WD. Clinicopathological significance of LRP16 protein in 336 gastric carcinoma patients. World J Gastroenterol 2009; 15: 4833-4837
8. Bennett MW, O'connell J, O'sullivan GC, Roche D, Brady C, Kelly J, Collins JK, Shanahan F. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut 1999; 44: 156-162
9. Memon SA, Hou J, Moreno MB, Zacharchuk CM. Apoptosis induced by a chimeric Fas/FLICE receptor: lack of requirement for Fas- or FADD-binding proteins. J Immunol 1998; 160: 2046-2049
10. Fukuzawa K, Takahashi K, Furuta K, Tagaya T, Ishikawa T, Wada K, Omoto Y, Koji T, Kakumu S. Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). J Gastroenterol 2001; 36: 681-688
11. Compagni A, Christofori G. Recent advances in research on multistage tumorigenesis. Br J Cancer 2000; 83: 1-5
12. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 1997; 3: 294-300
13. Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T, Nakajima Y. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 2002; 5: 61-68
14. Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bjørnbeth BA, Taskén K. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother 2008; 57: 813-821
15. Lee TB, Min YD, Lim SC, Kim KJ, Jeon HJ, Choi SM, Choi CH. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells. J Gastroenterol Hepatol 2002; 17: 32-38
16. Kume T, Oshima K, Yamashita Y, Shirakusa T, Kikuchi M. Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach. Int J Cancer 1999; 84: 339-343
17. Zhao XH, Gu SZ, Tian HG, Quan P, Pan BR. Clinical significance of expression of apoptotic signal proteins in gastric carcinoma tissue. World J Gastroenterol 2005; 11: 3846-3849
18. Hallermalm K, De Geer A, Kiessling R, Levitsky V, Levitskaya J. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res 2004; 64: 6775-6782
19. Shain KH, Landowski TH, Dalton WS. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 2002; 168: 2544-2553